Abstract
We cultured human bone marrow-derived stem cells on bovine bone slices in 96-well plates in the presence of M-CSF and RANKL, allowing them to differentiate into osteoclasts. Secreted TRACP 5b was a useful endpoint measurement to demonstrate effects of inhibitors of osteoclast differentiation in the culture system, reflecting accurately the number of formed osteoclasts. Inhibitors of osteoclast activity were added into the cultures after the differentiation period, and the cultures were continued to allow the formed osteoclasts to resorb bone. CTX values obtained after the resorption period were normalized with TRACP 5b values obtained after the differentiation period, before adding the inhibitors. This normalization prevents false results that could be obtained from the presence of different amounts of osteoclasts in different wells before adding the inhibitors. These results demonstrate that the use of TRACP 5b and CTX allows rapid and reliable testing of antiresorptive compounds in human osteoclast cultures.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Pierelli L, Scambia G, d’Onofrio G, Ciarli M, Fattorossi A, Bonanno G, Menichella G, Battaglia A, Benedetti Panici P, Tommasi M, Mancuso S, Leone G (1997) Generation of multinuclear tartrate-resistant acid phosphatase positive osteoclasts in liquid culture of purified human peripheral blood CD34+ progenitors. Br J Haematol 96:64–69
Quinn JM, Elliott J, Gillespie MT, Martin TJ (1998) A combination of osteoclast differentiation factor and macrophage-colony stimulating factor is sufficient for both human and mouse osteoclast formation in vitro. Endocrinology 139:4424–4427
Mbalaviele G, Jaiswal N, Meng A, Cheng L, Van Den Bos C, Thiede M (1999) Human mesenchymal stem cells promote human osteoclast differentiation from CD34+ bone marrow hematopoietic progenitors. Endocrinology 140:3736–3743
Boyde A, Ali NN, Jones SJ (1984) Resorption of dentine by isolated osteoclasts in vitro. Br Dent J 156:216–220
Chambers TJ, Revell PA, Fuller K, Athanasou NA (1984) Resorption of bone by isolated rabbit osteoclasts. J Cell Sci 66:383–399
Selander K, Lehenkari P, Väänänen HK (1994) The effects of bisphosphonates on the resorption cycle of isolated osteoclasts. Calcif Tissue Int 55:368–375
Christgau S, Rosenquist C, Alexandersen P, Bjarnason NH, Ravn P, Fledelius C, Herling C, Qvist P, Christiansen C (1998) Clinical evaluation of the Serum CrossLaps One Step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides. Clin Chem 44:2290–2300
Bagger YZ, Foged NT, Andersen L, Lou H, Qvist P (1999) CrossLaps for culture: an improved enzyme-linked immunosorbent assay (ELISA) for measuring bone resorption in vitro. J Bone Miner Res 14(suppl 1):S370 abstract
Halleen JM, Alatalo SL, Suominen H, Cheng S, Janckila AJ, Väänänen HK (2000) Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res 15:1337–1345
Stepan JJ, Silinkova-Malkova E, Havranek T, Formankova J, Zichova M, Lachmanova J, Strakova M, Broulik P, Pacovsky V (1983) Relationship of plasma tartrate resistant acid phosphatase to the bone isoenzyme of serum alkaline phosphatase in hyperparathyroidism. Clin Chim Acta 133:189–200
Alatalo SL, Halleen JM, Hentunen TA, Mönkkönen J, Väänänen HK (2000) Rapid screening method for osteoclast differentiation in vitro that measures tartrate-resistant acid phosphatase 5b activity secreted into the culture medium. Clin Chem 46:1751–1754
Chu P, Chao TY, Lin YF, Janckila AJ, Yam LT (2003) Correlation between histomorphometric parameters of bone resorption and serum type 5b tartrate-resistant acid phosphatase in uremic patients on maintenance hemodialysis. Am J Kidney Dis 41:1052–1059
Alatalo SL, Penq Z, Janckila AJ, Kaija H, Vihko P, Väänänen HK, Halleen JM (2003) A novel immunoassay for the determination of tartrate-resistant acid phosphatase 5b from rat serum. J Bone Miner Res 18:134–139
Alatalo SL, Ivaska KK, Waguespack SG, Econs MJ, Väänänen HK, Halleen JM (2004) Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonberg disease (type II autosomal dominant osteopetrosis). Clin Chem 50:883–890
Sörensen MG, Henriksen K, Schaller S, Henriksen DB, Nielsen FC, Dziegiel MH, Karsdal MA (2007) Characterization of osteoclasts derived from CD14+ monocytes isolated from peripheral blood. J Bone Miner Metab 25:36–45
Hannon RA, Clowes JA, Eagleton AC, Al Hadari AA, Eastell R, Blumsohn A (2004) Clinical performance of immunoreactive tartrate resistant acid phosphatase isoform 5b as a marker of bone resorption. Bone (NY) 34:187–194
Nenonen A, Cheng S, Ivaska KK, Alatalo SL, Lehtimäki T, Schmidt-Gayk H, Uusi-Rasi K, Heinonen A, Kannus P, Sievänen H, Vuori I, Väänänen HK, Halleen JM (2005) Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover. J Bone Miner Res 20:1804–1812
Acknowledgments
We thank Suvi Suutari and Salla Ylönen for their skillful technical assistance, and the Finnish Funding Agency for Technology and Innovations (TEKES) and TULES graduate school for financial support.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Rissanen, J.P., Ylipahkala, H., Fagerlund, K.M. et al. Improved methods for testing antiresorptive compounds in human osteoclast cultures. J Bone Miner Metab 27, 105–109 (2009). https://doi.org/10.1007/s00774-008-0002-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00774-008-0002-1